1. FDA granted accelerated approval for atrasentan for proteinuria reduction in IgA nephropathy (IgAN).
2. IgAN is a chronic immune-mediated glomerular disease with considerable heterogeneity in progression and a significant risk of kidney failure.
3. Atrasentan reduced proteinuria by 36.1% in adults with IgAN.
4. Effects were observed as early as week 6 and were sustained through week 36.
5. A generally favorable safety profile was found for atrasentan, although liver enzyme testing is recommended.
6. Continued approval depends on further verification of clinical benefit in the ongoing study until 2026. 

Source: Novartis